Alkermes still rated hold by Jefferies

Alkermes Inc. was reiterated by Jefferies & Co. Inc. analyst David Windley at a hold rating and an $18 price target. As expected Vivitrol received an approvable letter with minor follow-up required to gain full approval. The next likely catalyst is a clarification of regulatory pathway for exenatide LAR, Jefferies said. On Dec. 29, shares of the Cambridge, Mass., pharmaceutical company were up $1.86, or 10.46%, at $19.65 on volume of 9,962,347 shares versus the three-month running average of 1,087,140 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.